NL-OMON22641已完成不适用
A phase II study of erlotinib and bevacizumab in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) who have not received prior chemotherapy.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Roche
- 入组人数
- 46
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Cytologically or histologically advanced non-squamous NSCLC. Patients with squamous cell histology are eligible only if their intrathoracic disease has been completely resected, they have no current evidence of intrathoracic disease (with the exception of isolated pleural effusion), and they have not had hemoptysis in the 28 days prior to randomization;
- •2. No prior chemotherapy or therapy with systemic anti-tumor therapy (e.g., monoclonal antibody therapy) or prior exposure to agents directed at the HER axis (e.g. EGFR TK inhibitors, Herceptin). Prior surgery and/or localized irradiation is permitted provided that the irradiated lesion is not the only measurable lesion;
排除标准
- •1. Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, severe cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease);
- •2. Evidence of tumour invading major blood vessels;
研究者
相似试验
进行中（未招募）
不适用
A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapyHistologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histological subtypes: adenocarcinoma, planocellular or squamous cell carcinoma, and anaplastic/high-grade or undifferentiated carcinomaEUCTR2006-001308-35-DKThe Finsen Center, Rigshospitalet63
尚未招募
2 期
A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001non-squamous non-small cell lung cancerJPRN-UMIN000011791Itabashi Chuo Medical Center16
已完成
不适用
Phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous TreatmentRefractory or relapsed non-Squamous, non-small cell lung cancerJPRN-UMIN000004255Outpatient Oncology Unit, Kyoto University Hospital80
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study)on-Small Cell Lung CancerJPRN-UMIN000006459Kyushu University38
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer harboring EGFR mutation who acquired resistance to prior gefitinib treatment (TAILORED-1 study)on-Small Cell Lung CancerJPRN-UMIN000006457Kyushu University30